NASDAQ:NPCE
NeuroPace, Inc. Stock News
$7.53
-0.0700 (-0.92%)
At Close: May 24, 2024
Neuropace, Inc. (NPCE) Q3 2022 Earnings Call Transcript
08:55pm, Saturday, 12'th Nov 2022
Neuropace, Inc. (NASDAQ:NPCE ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Philip Taylor - Gilmartin Group Michael Favet - President, CEO & Director Rebecca Kuhn
NeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference
04:03pm, Friday, 04'th Nov 2022
MOUNTAIN VIEW, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, tod
NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022
04:03pm, Tuesday, 25'th Oct 2022
MOUNTAIN VIEW, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, tod
NeuroPace to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
04:06pm, Tuesday, 23'rd Aug 2022
MOUNTAIN VIEW, Calif. , Aug. 23, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, to
NeuroPace, Inc. (NPCE) CEO Mike Favet on Q2 2022 Results - Earnings Call Transcript
06:45am, Saturday, 13'th Aug 2022
NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Matt Bacso - Investor Relations Mike Favet - Chief Executive Officer Rebecca Kuhn - Chie
NeuroPace to Report Second Quarter 2022 Financial Results on August 11, 2022
04:03pm, Thursday, 21'st Jul 2022
MOUNTAIN VIEW, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, tod
NeuroPace, Inc.'s (NPCE) CEO Mike Favet on Q1 2022 Results - Earnings Call Transcript
10:47pm, Friday, 13'th May 2022
NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Matt Bacso – Investor Relations Mike Favet – Chief Executive Officer Rebecca Kuhn – C
NeuroPace to Present at the 2022 RBC Capital Markets Global Healthcare Conference
08:00am, Friday, 13'th May 2022
MOUNTAIN VIEW, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, t
Bear of the Day: NeuroPace (NPCE)
07:32am, Monday, 21'st Mar 2022
EPS estimates get slashed 50% but sales still expected to grow for this innovative epilepsy device
NeuroPace, Inc. (NPCE) Q4 2021 Earnings Call Transcript
01:00am, Friday, 11'th Mar 2022 The Motley Fool
NPCE earnings call for the period ending December 31, 2021.
NeuroPace, Inc. (NPCE) CEO Mike Favet on Q4 2021 Results - Earnings Call Transcript
11:54pm, Thursday, 10'th Mar 2022 Seeking Alpha
NeuroPace, Inc. 2021 Q4 - Results - Earnings Call Presentation
09:32pm, Thursday, 10'th Mar 2022 Seeking Alpha
NeuroPace GAAP EPS of -$0.44 misses by $0.10, revenue of $11M misses by $0.02M
09:10pm, Thursday, 10'th Mar 2022 Seeking Alpha
NeuroPace press release (NPCE): Q4 GAAP EPS of -$0.44 misses by $0.10.Revenue of $11M (+2.3% Y/Y) misses by $0.02M.
NeuroPace Reports Fourth Quarter & Full Year 2021 Financial Results
09:02pm, Thursday, 10'th Mar 2022 Investors Neuropace
MOUNTAIN VIEW, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2021.
NeuroPace Reports Fourth Quarter & Full Year 2021 Financial Results
09:02pm, Thursday, 10'th Mar 2022 GlobeNewswire
MOUNTAIN VIEW, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2021.
